Clinical Trial: Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Effect of Second-line Irinotecan and Capecitabine Versus Irinotecan Alone in Advanced Biliary Tract Cancer Patients Progressed After First-line Gemcitabine and Cisplatin: A Randomized Controlled Study
Brief Summary: This study is designed to investigate the effect of second-line irinotecan and capecitabine versus irinotecan alone for gemcitabine and cisplatin refractory advanced biliary tract cancer patients.
Detailed Summary:
Sponsor: Zhejiang University
Current Primary Outcome: Progression Free Survival [ Time Frame: within 1 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Overall Survival [ Time Frame: within 1 year ]
Original Secondary Outcome: Same as current
Information By: Zhejiang University
Dates:
Date Received: September 21, 2015
Date Started: September 2015
Date Completion: December 2017
Last Updated: November 29, 2015
Last Verified: November 2015